Guidance

Hepatitis A/Typhoid vaccine: patient group direction

PGD template to support the provision of hepatitis A/typhoid (HepA/Typhoid) vaccine, for travel.

• From: UK Health Security Agency
• Published: 23 February 2018
• Last updated: 11 December 2023 — See all updates

Applies to England

Documents

Hepatitis A/Typhoid vaccine: patient group direction

Ref: UKHSA gateway number GOV-11415

MS Word Document, 126 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Notice of extension of the validity of Hepatitis A/Typhoid vaccine PGD

MS Word Document, 118 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of HepA/Typhoid vaccine to individuals considered at risk of exposure to Salmonella enterica serovar typhi, (S. typhi) and hepatitis A virus, in accordance with recommendations from the National Travel Health Network and Centre (NaTHNaC).

HepA/Typhoid vaccine PGD version 3 is valid from 1 March 2022 and expires on 29 February 2024 and has been extended to 31 May 2024.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012).

Practitioners should follow local policy and procedures to access authorised PGD documents. This PGD template should be used with reference to current national guidance, Green Book, and Summary of Product Characteristics for the vaccine.

Published 23 February 2018
Last updated 11 December 2023 + show all updates

1. 11 December 2023

   Added notice of extension.

2. 21 February 2022

   Added version 3 (see page 2 for change history).

3. 28 January 2020

   Added V02.00: routine review.

4. 23 February 2018

   First published.